NDAORALTABLET
Approved
Jul 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEMADRIN (procyclidine hydrochloride) is an oral small-molecule anticholinergic agent used primarily to treat extrapyramidal side effects induced by antipsychotic medications. It has been in clinical use since 1955 and works by blocking cholinergic neurotransmission in the central nervous system.
LOE Approaching
As a mature product approaching loss of exclusivity with low competitive pressure (30%), this brand faces significant commercial headwinds and likely operates with a minimal, maintenance-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KEMADRIN offers limited career growth given its mature lifecycle, generic competition, and zero linked job openings. This role is suited for professionals seeking stability in a maintenance/legacy product environment rather than career advancement or innovation exposure.
Generic/Brand ManagerRegulatory Affairs
Worked on KEMADRIN at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.